珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
2022年12月23日 11:04:35来源:作者:

INGELHEIM, Germany & NEW YORK--(BUSINESS WIRE)--Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT). The companies will collaborate to develop and commercialize a novel mobile application, which combines multiple clinically validated therapeutic interventions for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes. The partnership aims to provide additional treatment options to those living with schizophrenia, where there remains a significant unmet need due to lack of access to psychosocial intervention therapies.

Schizophrenia is one of the 15 leading causes of disability worldwide, with approximately half of all patients exhibiting co-occurring mental and/or behavioral health disorders.1 It is a serious mental health condition that alters a person’s perception of reality and impacts how they think, feel, and behave, and people diagnosed with schizophrenia can remain functionally impaired due to insufficiently treated negative symptoms, including cognitive deficits and limited social functioning.2 Treatment guidelines recommend tailored psychosocial intervention therapies, however, access to these interventions is limited. 2,3 Providing novel, digital therapeutic options has the potential to significantly improve treatment and positively impact health and patient’s quality of life.

The additional prescription digital therapeutic under this expanded collaboration builds on development and clinical successes together with key patient insights gained under the companies’ existing collaboration, which has been in effect since September 2020. The CT-155 program has achieved all development milestones to-date and generated supportive data across clinical learning studies in advance of an upcoming pivotal registration study. The companies are pursuing this new therapy after recognizing that a comprehensive treatment strategy for schizophrenia would benefit from a multi-product approach. Click Therapeutics will receive an upfront payment, funding for research and development activities as well as clinical, regulatory and commercial milestone payments up to a total of USD 460 million, plus tiered royalties.

“We are very excited to expand our collaboration with Click Therapeutics and further tap into their expertise in developing efficacious and engaging digital therapeutics. This brings us an important step closer to our aim of developing holistic mental health solutions for patients in need. It opens new horizons on our journey toward advancing mental healthcare by combining pharmacotherapies with newly emerging digital technologies,” said Nedim Pipic, MD, Corporate Vice President, Therapeutic Area Head CNS, Retinopathies & Emerging Areas, Boehringer Ingelheim.

“Our collaboration with Boehringer Ingelheim offers significant potential to bring new digital treatment options to a currently underserved patient population,” said David Benshoof Klein, CEO, Click Therapeutics. “Our teams share a passion to pursue new, groundbreaking approaches to treatment and a mission to make a difference for patients. We are thrilled to expand our relationship with Boehringer Ingelheim to additional treatments within schizophrenia.”

“With this new project we are addressing symptoms of patients for which no scalable treatment approaches exist today. Seeing the pipeline of PDTs growing reflects our commitment to mental health. We are excited to realize the potential of complementing pharmacological therapy with digital solutions to transform the lives of patients,” added Cornelia Dorner-Ciossek, Ph.D., Digital Health Lead at Boehringer Ingelheim.

“Expanding our successful partnership with Boehringer Ingelheim enables our team to build on the experience and insights gathered with CT-155 and further expand the scope of our digital therapeutics platform,” said Austin Speier, Chief Strategy Officer, Click Therapeutics. “This growing collaboration is a testament to the progress we have achieved so far working together and creates the inspiring opportunity to expand CT-155 into a seamless digital therapy suite that can deliver meaningful outcomes to people living with schizophrenia.”

For the full press release and link to ‘Notes to Editors’ please click here:

Press Release

责任编辑: admin

看新闻,关注新闻

本网网友:永远别回头
评论:你那么喜欢劈腿,怎么不去跳芭蕾舞。

淘宝网友:不帶這么玩的
评论:姐姐曾对我说:妹子你真好看!背面看,想犯罪;侧面看,想到退;正面看,想正当防卫。

天猫网友:memory’青春
评论:我横溢的不只是才华而已,其实还有腰间的脂肪。

腾讯网友:曲终人离场
评论:虎落平阳被犬欺、落配凤凰不如鸡 。

猫扑网友:以死换温柔◇
评论:从小就有一个敌人叫“别人家的小孩”。他不爱玩游戏,从来只知道学习。

百度网友:别走停下来
评论:我愿意为你摘一颗星,只要你借给我足够高的椅子。

天涯网友:Cold-blooded 凉薄
评论:我知道强扭的瓜不甜,但是本人就是不喜欢吃甜瓜。

搜狐网友:自戀的病源
评论:什么是兄弟?兄弟就是50年后你老了躺在床上,我问你喝水不?你摇头。吃水果不?你还是摇头。我再问:给你找个妞?你睁大眼睛,眼里闪着泪花。兄弟,扶我起来试试。。。

其它网友:猥琐 先森 Lasa°
评论:再过五十年我就是古董了,所以你趁现在赶紧好好收藏我吧

凤凰网友:遗忘。Forgotten.
评论:终于知道为什么军训要左右转动了,因为这样晒得均匀。

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!